Swixx BioPharma is designed to fully replace biopharma, OTC and medical device multinationals’ subsidiaries or business units in those countries, or therapeutic areas of CEE, that the multinational chooses not to enter, or to exit
Location: Switzerland
Employees: 201-500
Phone: +41 41 552 34 40
Total raised: $121.88M
Valuation: $1.75B
Founded date: 2013
Investors 1
| Date | Name | Website |
| - | HBM Partne... | hbmpartner... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 21.05.2021 | - | $121.88M | - |
Mentions in press and media 13
| Date | Title | Description |
| 19.08.2026 | Российская фармкомпания стала лидером по выплатам врачам и медорганизациям | Российская фармкомпания стала лидером по выплатам врачам и медорганизациям Иностранные игроки все меньше тратят на исследования «Р-Фарм» потратил на выплаты врачам и организациям в 2025 году 2,2 млрд руб., больше, чем любой другой член Ассо... |
| 10.08.2026 | Суд отказал «Биохимику» в принудительной лицензии на долутегравир | Суд отказал «Биохимику» в принудительной лицензии на долутегравир Арбитражный суд Москвы отказал «Биохимику» (входит в ГК «Промомед») в принудительной лицензии на использование патента ViiV Healthcare Company и японской Shionogi, защищающег... |
| 17.12.2025 | SK Capital Invests Big in Biopharma Powerhouse Swixx | SK Capital Partners acquired a majority stake in Swixx Biopharma AG, valuing the biopharma commercialization leader over EUR 1.5 billion. This strategic investment boosts Swixx's global expansion and growth in underserved pharmaceutical mar... |
| 15.12.2025 | SK Capital acquires majority stake in Swixx Biopharma at EUR 1.5 billion valuation | HBM Healthcare Investments, an investment company focused on the healthcare sector, has announced the signing of a binding agreement to sell a majority stake in Swixx Biopharma. Swixx Biopharma has delivered exceptional growth, with revenu... |
| 15.12.2025 | SK Capital Announces Definitive Agreement to Invest in Swixx BioPharma AG to Drive the Next Phase of Growth and Global Expansion | SK Capital Partners, LP (“SK Capital”), a New York-based private investment firm focused on the life sciences, specialty materials, and ingredients sectors, today announced that its affiliate has reached an agreement to invest in Swixx BioP... |
| 12.11.2025 | Lundbeck delivers 14% CER revenue growth, reflecting stronger momentum from Vyepti® and Rexulti® driven by additional investments | VALBY, Denmark, Nov. 12, 2025 /PRNewswire/ -- Key highlights Lundbeck's total revenue grew by +14% CER[1] (+13% DKK) to DKK 18,537 million in the first nine months of 2025. Growth in the U.S. and Europe was the driver of this strong perform... |
| 11.11.2025 | Lundbeck delivers 14% CER revenue growth, reflecting stronger momentum from Vyepti[®] and Rexulti[®] driven by additional investments | Lundbeck delivers 14% CER revenue growth, reflecting stronger momentum from Vyepti[®] and Rexulti[®] driven by additional investments Tue, Nov 11, 2025 15:34 CET Report this content Key highlights Lundbeck’s total revenue grew by +14% CER[1... |
| 10.09.2025 | HBM Portfolio Company Swixx BioPharma and Lundbeck Sign Multi-Regional CNS Partnership | HBM Healthcare Investments, a leading investor in global healthcare companies, announces that its portfolio company Swixx BioPharma, and its affiliated companies (Swixx) have signed a transformative, multi-regional distribution and services... |
| 09.09.2025 | Lundbeck sharpens commercial focus in line with strategy, initiates partnering in 27 markets by end-2025 | Lundbeck sharpens commercial focus in line with strategy, initiates partnering in 27 markets by end-2025 Tue, Sep 09, 2025 14:30 CET Report this content Three new regional partnerships will secure continuity of today’s commercial activities... |
| 24.05.2024 | Following a strategic acquisition, Swixx BioPharma expects a turnover exceeding one billion | Swixx BioPharma was created to replace biopharma, OTC and medical device multinationals’ subsidiaries in those countries, or therapeutic areas, that its partners choose not to enter, or to exit. The company based in den canton of Zug expan... |
Show more